NewsStocksGlenmark Pharmaceuticals Launches Epinephrine Injection in US Market Worth $67.60 MillionGlenmark Pharmaceuticals Launches Epinephrine Injection in US Market Worth $67.60 Million
Glenmark Pharmaceuticals Inc., USA has launched Epinephrine Injection USP, 30mg/30mL (1mg/mL) Multiple-Dose Vial, targeting a significant market opportunity worth approximately $67.60 million annually. The product is bioequivalent to the reference drug from BPI Labs and strengthens the company's institutional channel portfolio while providing quality, affordable alternatives to patients.
*this image is generated using AI for illustrative purposes only.
Glenmark Pharmaceuticals Inc., USA has announced the launch of Epinephrine Injection USP, 30mg/30mL (1mg/mL) Multiple-Dose Vial. This strategic product launch expands the company's portfolio within the institutional channel and targets a market worth approximately $67.60 million annually.
Product Details and Market Positioning
The newly launched Epinephrine Injection is bioequivalent and therapeutically equivalent to the reference listed drug, Epinephrine Injection USP, 30mg/30mL (1mg/mL) of BPI Labs, LLC, NDA 205029. This ensures that patients receive the same therapeutic benefits as the original formulation while potentially benefiting from more competitive pricing.
| Parameter: | Details |
|---|---|
| Product Name: | Epinephrine Injection USP |
| Strength: | 30mg/30mL (1mg/mL) |
| Formulation: | Multiple-Dose Vial |
| Reference Drug: | BPI Labs, LLC (NDA 205029) |
| Market Size: | $67.60 million annually |
Market Opportunity and Financial Impact
According to IQVIA sales data, the Epinephrine Injection USP, 30mg/30mL (1mg/mL) market achieved annual sales of approximately $67.60 million. This represents a significant market opportunity for Glenmark Pharmaceuticals as it seeks to capture market share in this established therapeutic segment.
Management Commentary
Marc Kikuchi, President Business Head, North America, expressed enthusiasm about the launch, stating that the company is excited to announce the launch of Epinephrine Injection USP, 30mg/30mL (1mg/mL) Multiple-Dose Vial. He emphasized that this launch grows their portfolio of products within the institutional channel while strengthening their commitment to bringing quality and affordable alternatives to market for patients.
Regulatory and Compliance Information
Glenmark's Epinephrine Injection USP, 30mg/30mL (1mg/mL) Multiple-Dose Vial is approved only for the indications listed in Glenmark's approved label. The company has ensured full regulatory compliance before bringing this product to market, maintaining its standards for quality and safety in pharmaceutical manufacturing.
Historical Stock Returns for Glenmark Pharmaceuticals
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +1.00% | -0.41% | +4.30% | +18.62% | +27.68% | +307.67% |
19
